Olaparib: all 338 studies that test it
Page 3 of 4. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.
- D9319C00001- 1L OC Mono Global RCTActive, not recruitingNCT04884360Phase 3
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
- Functional Analysis of BRCAnessTerminatedNCT04780945Phase 2
- Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Active, not recruitingNCT04753879Phase 2
- Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)Active, not recruitingNCT04748042Phase 2
- Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO TrialActive, not recruitingNCT04728230Phase 1/2
- Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain MetastasesActive, not recruitingNCT04711824Phase 1/2
- EP0057 in Combination With Olaparib in Advanced Ovarian CancerCompletedNCT04669002Phase 2
- A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based TherapyActive, not recruitingNCT04666740Phase 2
- Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT04643379Phase 2
- Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical CancerStatus unknownNCT04641728Phase 2
- Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) MutationStatus unknownNCT04633902Phase 2
- Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active, not recruitingNCT04624204Phase 3
- Study of Pamiparib in Newly Diagnosed and rGBMCompletedNCT04614909Early Phase 1
- Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical CystectomyTerminatedNCT04579133Phase 2
- Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerStatus unknownNCT04566952Phase 2
- A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical CancerActive, not recruitingNCT04487587Phase 2
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With OlaparibActive, not recruitingNCT04421963Phase 3
- Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian CancerCompletedNCT04417192Phase 2
- Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine CancerActive, not recruitingNCT04394858Phase 2
- Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingNCT04380636Phase 3
- 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive TumoursCompletedNCT04375267Phase 1
- Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.Active, not recruitingNCT04348045Phase 2
- DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract CancerActive, not recruitingNCT04298021Phase 2
- NUVOLA TRIAL Open-label Multicentre StudyStatus unknownNCT04261465Phase 2
- A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.WithdrawnNCT04239014Phase 2
- Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid TumoursCompletedNCT04236414Phase 1
- Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib TreatmentActive, not recruitingNCT04169841Phase 2
- Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)CompletedNCT04123366Phase 2
- Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational StudyStatus unknownNCT04091204Phase 2
- ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingNCT04065269Phase 2
- Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Active, not recruitingNCT04053322Phase 2
- PARP Inhibition During Pre-surgical Window in Breast/Ovary CancerCompletedNCT04041128Early Phase 1
- Study of Olaparib and Durvalumab in IDH-Mutated Solid TumorsActive, not recruitingNCT03991832Phase 2
- Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination GenesActive, not recruitingNCT03967938Phase 2
- Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall RecurrencesTerminatedNCT03955640Phase 1
- Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before SurgeryActive, not recruitingNCT03943173Early Phase 1
- Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast CancerTerminatedNCT03931551Phase 2
- Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersTerminatedNCT03924245Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT03874884Phase 1
- Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsActive, not recruitingNCT03851614Phase 2
- Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.CompletedNCT03838744Phase 2
- A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric CancerStatus unknownNCT03829345Phase 2
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
- Olaparib for PAH: a Multicenter Clinical TrialTerminatedNCT03782818Phase 1/2
- UTOLA: UTerin OLAparibCompletedNCT03745950Phase 2
- Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast CancerActive, not recruitingNCT03742245Phase 1
- HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerCompletedNCT03685331Phase 1
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsActive, not recruitingNCT03682289Phase 2
- Olaparib + Sapacitabine in BRCA Mutant Breast CancerActive, not recruitingNCT03641755Phase 1
- Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast CancerActive, not recruitingNCT03598257Phase 2
- Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast CancerActive, not recruitingNCT03594396Phase 1/2
- Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric CancerActive, not recruitingNCT03579784Phase 2
- Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03579316Phase 2
- ARQ761 + PARP Inhibitor in Refractory Solid TumorsWithdrawnNCT03575078Phase 1
- Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?Status unknownNCT03570437Phase 2
- Olaparib in Recurrent IDH-mutant GliomaCompletedNCT03561870Phase 2
- Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast CancerCompletedNCT03544125Phase 1
- Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)CompletedNCT03534492Phase 2
- Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyCompletedNCT03534453Phase 3
- Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian CarcinomaCompletedNCT03470805Phase 2
- Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)CompletedNCT03434158Phase 2
- Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]CompletedNCT03428607Phase 2
- IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOCCompletedNCT03378297Early Phase 1
- Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic ChangesActive, not recruitingNCT03375307Phase 2
- A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single AgentTerminatedNCT03367689Phase 2
- Olaparib In Metastatic Breast CancerActive, not recruitingNCT03344965Phase 2
- Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPCCompletedNCT03263650Phase 2
- Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell TransplantCompletedNCT03259503Phase 1
- Olaparib for PAH: a Pilot StudyTerminatedNCT03251872Early Phase 1
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2
- Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas PatientsActive, not recruitingNCT03212742Phase 1/2
- The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknownNCT03182634Phase 2
- Selumetinib and Olaparib in Solid TumorsActive, not recruitingNCT03162627Phase 1
- Resistant Ovarian Cancer, Olaparib and Liposomal DoxorubicinCompletedNCT03161132Phase 2
- Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid TumorsCompletedNCT03127215Phase 2
- Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian CancerCompletedNCT03117933Phase 2
- Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)CompletedNCT03109080Phase 1
- A Dye for the Detection of Cancer of the Tongue and MouthActive, not recruitingNCT03085147Phase 1/2
- Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid TumorsCompletedNCT03057145Phase 1
- A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).CompletedNCT03022409Phase 1
- Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair DefectsActive, not recruitingNCT03012321Phase 2
- Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A MutationsCompletedNCT03009682Phase 2
- Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.CompletedNCT02882308Phase 2
- Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian CancerCompletedNCT02855697Early Phase 1
- Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian CancerStatus unknownNCT02822157Phase 2
- Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer PatientsCompletedNCT02755844Phase 1/2
- Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCCWithdrawnNCT02686008Phase 1
- Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid TumorsStatus unknownNCT02684318Phase 1/2
- Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer PatientsStatus unknownNCT02681562Phase 2
- A Study of Cediranib and Olaparib at Disease Worsening in Ovarian CancerCompletedNCT02681237Not applicable
- Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung CancerTerminatedNCT02679963Phase 2
- PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian CancerActive, not recruitingNCT02571725Phase 1/2
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1
- Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell TumorCompletedNCT02533765Phase 2
- AZD1775 Combined With Olaparib in Patients With Refractory Solid TumorsCompletedNCT02511795Phase 1
- Efficacy and Safety of PARPi to Treat Pancreatic CancerCompletedNCT02511223Phase 2
- Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)TerminatedNCT02485990Phase 1
- Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...Active, not recruitingNCT02484404Phase 1/2